Princeton Alpha Management’s Haemonetics HAE Stock Holding History

Princeton Alpha Management’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-11,336	Closed	-$397K	–	841
2016 Q1	$397K	Buy	11,336 +4,572	+68%	+$148K	0.06%	416
2015 Q4	$218K	Sell	6,764 -3,594	-35%	-$117K	0.04%	605
2015 Q3	$335K	Buy	10,358 +4,238	+69%	+$159K	0.07%	430
2015 Q2	$253K	Buy	+6,120	New	+$258K	0.05%	516
2014 Q2	–	Sell	-10,838	Closed	-$353K	–	750
2014 Q1	$353K	Buy	+10,838	New	+$414K	0.11%	291

Other funds holding HAE

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.78B AUM 5.83% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

VBA

Van Berkom & Associates Montreal, Quebec, Canada $3.1B AUM 12.88% 1-Year Est. Return

Princeton Alpha Management's HAE Position: Q2 2016 in Review

Princeton Alpha Management sold out of Haemonetics (HAE) in Q2 2016, closing a stake of 11,336 shares — an estimated $397K sold.

Princeton Alpha Management first reported a position in HAE in Q1 2014 and held it in 5 quarters. The position peaked at $397K in Q1 2016. 178 funds tracked by Wall St. Rank hold HAE as of Q2 2016.

Princeton Alpha Management reported no remaining Haemonetics position as of Q2 2016 after selling out during the quarter.
Princeton Alpha Management sold 11,336 Haemonetics shares in Q2 2016, an estimated $397K.
Princeton Alpha Management first reported a position in Haemonetics in Q1 2014 and held it in 5 quarters.
Princeton Alpha Management's Haemonetics position peaked at $397K in Q1 2016.
178 funds tracked by Wall St. Rank held Haemonetics as of Q2 2016.

Based on Princeton Alpha Management's 13F filing for Q2 2016, filed 5 Aug 2016.